Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2009, Article ID 424935, 8 pages
http://dx.doi.org/10.1155/2009/424935
Review Article

Controversies on Rituximab Therapy in Sjögren Syndrome-Associated Lymphoproliferation

1Rheumatology Clinic, DPMSC, Azienda Ospedaliero Universitaria “S. Maria della Misericordia”, University of Udine, 33100 Udine, Italy
2U.O.C. di Medicina, Presidio Ospedaliero di San Daniele del Friuli, San Daniele del Friuli, 33038 Udine, Italy

Received 28 February 2009; Accepted 15 December 2009

Academic Editor: Debashish Danda

Copyright © 2009 Luca Quartuccio et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. N. Skopouli, U. Dafni, J. P. A. Ioannidis, and H. M. Moutsopoulos, “Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome,” Seminars in Arthritis and Rheumatism, vol. 29, no. 5, pp. 296–304, 2000. View at Google Scholar
  2. K. E. Smedby, C. M. Vajdic, M. Falster et al., “Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium,” Blood, vol. 111, no. 8, pp. 4029–4038, 2008. View at Publisher · View at Google Scholar · View at PubMed
  3. B. G. Somer, D. E. Tsai, L. Downs, B. Weinstein, and S. J. Schuster, “Improvement in Sjögren's syndrome following therapy with rituximab for marginal zone lymphoma,” Arthritis Care and Research, vol. 49, no. 3, pp. 394–398, 2003. View at Google Scholar
  4. S. De Vita, V. De Re, D. Gasparotto et al., “Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma,” Arthritis and Rheumatism, vol. 43, no. 1, pp. 94–102, 2000. View at Publisher · View at Google Scholar
  5. S. De Vita, G. De Marchi, S. Sacco, E. Gremese, M. Fabris, and G. Ferraccioli, “Preliminary classification of nonmalignant B cell proliferation in Sjögren's syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach,” Blood Cells, Molecules, and Diseases, vol. 27, no. 4, pp. 757–766, 2001. View at Publisher · View at Google Scholar · View at PubMed
  6. M. Voulgarelis and F. N. Skopouli, “Clinical, immunologic, and molecular factors predicting lymphoma development in Sjögren's syndrome patients,” Clinical Reviews in Allergy and Immunology, vol. 32, no. 3, pp. 265–274, 2007. View at Publisher · View at Google Scholar · View at PubMed
  7. X. Mariette, S. Roux, J. Zhang et al., “The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome,” Annals of the Rheumatic Diseases, vol. 62, no. 2, pp. 168–171, 2003. View at Publisher · View at Google Scholar
  8. F. Mackay, F. Sierro, S. T. Grey, and T. P. Gordon, “The BAFF/APRIL system: an important player in systemic rheumatic diseases,” Current Directions in Autoimmunity, vol. 8, pp. 243–265, 2005. View at Google Scholar
  9. F. Mackay, S. A. Woodcock, P. Lawton et al., “Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations,” Journal of Experimental Medicine, vol. 190, no. 11, pp. 1697–1710, 1999. View at Publisher · View at Google Scholar
  10. D. Gasparotto, S. De Vita, V. De Re et al., “Extrasalivary lymphoma development in Sjögren's syndrome: clonal evolution from parotid gland lymphoproliferation and role of local triggering,” Arthritis and Rheumatism, vol. 48, no. 11, pp. 3181–3186, 2003. View at Publisher · View at Google Scholar · View at PubMed
  11. J. Pijpe, G. W. van Imhoff, A. Vissink et al., “Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjögren's syndrome and associated MALT lymphoma,” Annals of the Rheumatic Diseases, vol. 64, no. 6, pp. 958–960, 2005. View at Publisher · View at Google Scholar · View at PubMed
  12. R. Seror, C. Sordet, L. Guillevin et al., “Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome,” Annals of the Rheumatic Diseases, vol. 66, no. 3, pp. 351–357, 2007. View at Publisher · View at Google Scholar · View at PubMed
  13. S. De Vita, G. De Marchi, S. Sacco, F. Zaja, C. A. Scott, and G. Ferraccioli, “Treatment of B-cell disorders of MALT in Sjögren's syndrome with anti-CD20 monoclonal antibody,” in Proceedings of the 8th International Symposium on Sjögren's Syndrome, p. 51, Kanazawa, Japan, May 2002, P8-2.
  14. W.-J. Shih, N. Ghesani, Z. Hongming, A. Alavi, S. Schusper, and D. Mozley, “F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjögren's syndrome before and after anti-CD20 antibody rituximab therapy,” Clinical Nuclear Medicine, vol. 27, no. 2, pp. 142–143, 2002. View at Publisher · View at Google Scholar
  15. M. Voulgarelis, S. Giannouli, D. Anagnostou, and A. G. Tzioufas, “Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas,” Rheumatology, vol. 43, no. 8, pp. 1050–1053, 2004. View at Publisher · View at Google Scholar · View at PubMed
  16. K. C. Harner, L. W. Jackson, and J. J. Drabick, “Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjögren's syndrome,” Rheumatology, vol. 43, no. 10, pp. 1309–1310, 2004. View at Publisher · View at Google Scholar · View at PubMed
  17. M. Ramos-Casals, A. López-Guillermo, P. Brito-Zerón, R. Cervera, and J. Font, “Treatment of B-cell lymphoma with rituximab in two patients with Sjögren's syndrome associated with hepatitis C virus infection,” Lupus, vol. 13, no. 12, pp. 969–971, 2004. View at Publisher · View at Google Scholar
  18. J.-E. Gottenberg, L. Guillevin, O. Lambotte et al., “Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases,” Annals of the Rheumatic Diseases, vol. 64, no. 6, pp. 913–920, 2005. View at Publisher · View at Google Scholar · View at PubMed
  19. M. Voulgarelis, S. Giannouli, A. G. Tzioufas, and H. M. Moutsopoulos, “Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone),” Annals of the Rheumatic Diseases, vol. 65, no. 8, pp. 1033–1037, 2006. View at Publisher · View at Google Scholar · View at PubMed
  20. J. Pijpe, G. W. van Imhoff, F. K. L. Spijkervet et al., “Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study,” Arthritis and Rheumatism, vol. 52, no. 9, pp. 2740–2750, 2005. View at Publisher · View at Google Scholar · View at PubMed
  21. L. Quartuccio, M. Fabris, M. Moretti et al., “Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma,” The Open Rheumatology Journal, vol. 2, pp. 38–43, 2008. View at Google Scholar
  22. J. Carbone, R. Perez-Fernandez, A. Muñoz, P. Sabin, L. Carreño, and E. Fernandez-Cruz, “Combined therapy with rituximab plus cyclophosphamide/vincristine/prednisone for Sjögren's syndrome-associated B-cell non-Hodgkin's lymphoma,” Clinical Reviews in Allergy and Immunology, vol. 34, no. 1, pp. 80–84, 2008. View at Publisher · View at Google Scholar · View at PubMed
  23. S. De Vita, G. De Marchi, S. Sacco, E. Gremese, M. Fabris, and G. Ferraccioli, “Preliminary classification of nonmalignant B cell proliferation in Sjögren's syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach,” Blood Cells, Molecules, and Diseases, vol. 27, no. 4, pp. 757–766, 2001. View at Publisher · View at Google Scholar · View at PubMed
  24. N. Talal and J. J. Bunim, “The development of malignant lymphoma in the course of Sjögren's syndrome,” The American Journal of Medicine, vol. 36, no. 4, pp. 529–540, 1964. View at Google Scholar
  25. S. S. Kassan, T. L. Thomas, H. M. Moutsopoulos et al., “Increased risk of lymphoma in sicca syndrome,” Annals of Internal Medicine, vol. 89, no. 6, pp. 888–892, 1978. View at Google Scholar
  26. J. A. DiGiuseppe, R. L. Corio, and W. H. Westra, “Lymphoid infiltrates of the salivary glands: pathology, biology, and clinical significance,” Current Opinion in Oncology, vol. 8, no. 3, pp. 232–237, 1996. View at Google Scholar
  27. D. I. Stott, F. Hiepe, M. Hummel, G. Steinhauser, and C. Berek, “Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjögren's syndrome,” Journal of Clinical Investigation, vol. 102, no. 5, pp. 938–946, 1998. View at Google Scholar
  28. T. C. Adamson III, R. I. Fox, D. M. Frisman, and F. V. Howell, “Immunohistologic analysis of lymphoid infiltrates in primary Sjögren's syndrome using monoclonal antibodies,” Journal of Immunology, vol. 130, no. 1, pp. 203–208, 1983. View at Google Scholar
  29. D. Boumba, F. N. Skopouli, and H. M. Moutsopoulos, “Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjögren's syndrome,” British Journal of Rheumatology, vol. 34, no. 4, pp. 326–333, 1995. View at Google Scholar
  30. S. De Vita, M. Boiocchi, D. Sorrentino et al., “Characterization of prelymphomatous stages of B cell lymphoproliferation in Sjögren's syndrome,” Arthritis and Rheumatism, vol. 40, no. 2, pp. 318–331, 1997. View at Publisher · View at Google Scholar
  31. S. De Vita, V. De Re, D. Gasparotto et al., “Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma,” Arthritis and Rheumatism, vol. 43, no. 1, pp. 94–102, 2000. View at Publisher · View at Google Scholar
  32. F. Barone, M. Bombardieri, M. M. Rosado et al., “CXCL13, CCL21, and CXCL12 expression in salivary glands of patients with Sjögren's syndrome and MALT lymphoma: association with reactive and malignant areas of lymphoid organization,” Journal of Immunology, vol. 180, no. 7, pp. 5130–5140, 2008. View at Google Scholar
  33. F. Lavie, C. Miceli-Richard, J. Quillard, S. Roux, P. Leclerc, and X. Mariette, “Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome,” Journal of Pathology, vol. 202, no. 4, pp. 496–502, 2004. View at Publisher · View at Google Scholar · View at PubMed
  34. P. Szodoray, S. Jellestad, M. O. Teague, and R. Jonsson, “Attenuated apoptosis of B cell activating factor-expressing cells in primary Sjögren's syndrome,” Laboratory Investigation, vol. 83, no. 3, pp. 357–365, 2003. View at Google Scholar
  35. M. Ittah, C. Miceli-Richard, J.-E. Gottenberg et al., “B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome,” Arthritis Research and Therapy, vol. 8, no. 2, article R51, 2006. View at Publisher · View at Google Scholar · View at PubMed
  36. M. Batten, C. Fletcher, L. G. Ng et al., “TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma,” Journal of Immunology, vol. 172, no. 2, pp. 812–822, 2004. View at Google Scholar
  37. J.-O. Pers, V. Devauchelle, C. Daridon et al., “BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjören's syndrome,” Arthritis and Rheumatism, vol. 56, no. 5, pp. 1464–1477, 2007. View at Publisher · View at Google Scholar · View at PubMed
  38. S. De Vita, F. Zaja, S. Sacco, A. De Candia, R. Fanin, and G. Ferraccioli, “Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells,” Arthritis and Rheumatism, vol. 46, no. 8, pp. 2029–2033, 2002. View at Publisher · View at Google Scholar · View at PubMed
  39. M. Voulgarelis, U. G. Dafni, D. A. Isenberg, and H. M. Moutsopoulos, “Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European concerted action on Sjögren's syndrome,” Arthritis and Rheumatism, vol. 42, no. 8, pp. 1765–1772, 1999. View at Publisher · View at Google Scholar
  40. Q. Gong, Q. Ou, S. Ye et al., “Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy,” Journal of Immunology, vol. 174, no. 2, pp. 817–826, 2005. View at Google Scholar
  41. A. C. Wotherspoon, C. Doglioni, T. C. Diss et al., “Regression of primary low-grade-B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori,” The Lancet, vol. 342, no. 8871, pp. 575–577, 1993. View at Publisher · View at Google Scholar